Missense mutations in the gene encoding prothrombin corresponding to Arg596 cause antithrombin resistance and thrombomodulin resistance

Summary

Antithrombin (AT) and thrombomodulin (TM) play important roles in the process of natural anticoagulation in vivo. Recently, we reported that the prothrombin Yukuhashi mutation (p.Arg596Leu) was associated with AT and TM resistance-related thrombophilia. To assess the AT and TM resistances associated with other missense mutations by single base substitution in the Arg596 codon, we generated recombinant variants (596Gln, 596Trp, 596Gly, and 596Pro) and investigated the effects on AT and TM anticoagulant functions. All variants except 596Pro were secreted in amounts comparable to that of the wild-type but exhibited variable procoagulant activities. After a 30-minute inactivation by AT, the relative residual activity of wild-type thrombin decreased to 15 ± 4.0%, in contrast to values of all variants were maintained at above 80%. The thrombin–AT complex formation, as determined by enzyme-linked immunosorbent assay, was reduced with all tested variants in the presence and absence of heparin. In the presence of soluble TM (sTM), the relative fibrinogen clotting activity of wild-type thrombin decreased to 16 ± 0.12%, whereas that of tested variants was 37%–56%. In a surface plasmon resonance assay, missense Arg596 mutations reduced thrombin–TM affinity to an extent similar to the reduction of fibrinogen clotting inhibition. In the presence of sTM or cultured endothelial-like cells, APC generation was enhanced differently by variant thrombins in a thrombin–TM affinity- dependent manner. These data indicate that prothrombin Arg596 missense mutations lead to AT and TM resistance in the variant thrombins and suggest that prothrombin Arg596 is important for AT- and TM- mediated anticoagulation.

Keywords

Prothrombin - missense variant - Arg596 - antithrombin resistance - thrombomodulin resistance

• References

• 1 Bauduer F, Lacombe D. Factor V Leiden, prothrombin 20210A, methylenetet-rahydrofolate reductase 677T, and population genetics. Mol Genet Metab 2005; 86: 91-99.
• 2 Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-1173.
• 3 Khan S, Dickerman JD. Hereditary thrombophilia. Thromb J 2006; 04: 15.
• 4 Dahlbäck B. Advances in understanding pathogenic mechanisms of thrombo-philic disorders. Blood 2008; 112: 19-27.
• 5 Bafunno V, Margaglione M. Genetic basis of thrombosis. Clin Chem Lab Med 2010; 48 (Suppl. 01) S41-51.
• 6 Butenas S, Mann KG. Blood coagulation. Biochemistry 2002; 67: 03-12.
• 7 Miyawaki Y, Suzuki A, Fujita J. et al. Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med 2012; 366: 2390-2396.
• 8 Djordjevic V, Kovac M, Miljic P. et al. A novel prothrombin mutation in two families with prominent thrombophilia--the first cases of antithrombin resistance in a Caucasian population. J Thromb Haemost 2013; 11: 1936-1939.
• 9 Bulato C, Radu CM, Campello E. et al. New Prothrombin Mutation (Arg596Trp, Prothrombin Padua 2) Associated With Venous Thromboembolism. Arterioscler Thromb Vasc Biol 2016; 36: 1022-1029.
• 10 Takagi Y, Kato I, Ando Y. et al. Antithrombin-resistant prothrombin Yukuhashi mutation also causes thrombomodulin resistance in fibrinogen clotting but not in protein C activation. Thromb Res 2014; 134: 914-917.
• 11 Li W, Johnson DJ, Esmon CT. et al. Structure of the antithrombin-thrombin-he-parin ternary complex reveals the antithrombotic mechanism of heparin. Nat Struct Mol Biol 2004; 11: 857-862.
• 12 Di Cera E, Dang QD, Ayala YM. Molecular mechanisms of thrombin function. Cell Mol Life Sci 1997; 53: 701-730.
• 13 Suzuki A, Nakashima D, Miyawaki Y. et al. A novel ENG mutation causing impaired co-translational processing of endoglin associated with hereditary hemorrhagic telangiectasia. Thromb Res 2012; 129: e200-208.
• 14 Suzuki A, Sanda N, Miyawaki Y. et al. Down-regulation of PROS1 gene expression by 17beta-estradiol via estrogen receptor alpha (ERalpha)-Sp1 interaction recruiting receptor-interacting protein 140 and the corepressor-HDAC3 complex. J Biol Chem 2010; 285: 13444-13453.
• 15 Ito H, Murakami M, Furuhata A. et al. Transcriptional regulation of neutral sphingomyelinase 2 gene expression of a human breast cancer cell line, MCF-7, induced by the anti-cancer drug, daunorubicin. Biochim Biophys Acta 2009; 1789: 681-690.
• 16 Lundblad RL, Kingdon HS, Mann KG. Thrombin. Methods Enzymol 1976; 45: 156-176.
• 17 Murata M, Takagi A, Suzuki A. et al. Development of a new laboratory test to evaluate antithrombin resistance in plasma. Thromb Res 2014; 133: 293-298.
• 18 Rubio R, Almagro D, Cruz A. et al. Prothrombin Habana: a new dysfunctional molecule of human prothrombin associated with a true prothrombin deficiency. Br J Haematol 1983; 54: 553-560.
• 19 Rocha E, Paramo JA, Bascones C. et al. Prothrombin Segovia: a new congenital abnormality of prothrombin. Scand J Haematol 1986; 36: 444-449.
• 20 Poort SR, Michiels JJ, Reitsma PH. et al. Homozygosity for a novel missense mutation in the prothrombin gene causing a severe bleeding disorder. Thromb Haemost 1994; 72: 819-824.
• 21 Pechik I, Madrazo J, Mosesson MW. et al. Crystal structure of the complex between thrombin and the central “E” region of fibrin. Proc Natl Acad Sci USA 2004; 101: 2718-2723.
• 22 Dang OD, Vindigni A, Di Cera E. An allosteric switch controls the procoagulant and anticoagulant activities of thrombin. Proc Natl Acad Sci USA 1995; 92: 5977-5981.
• 23 Pineda AO, Carrell CJ, Bush LA. et al. Molecular dissection of Na+ binding to thrombin. J Biol Chem 2004; 279: 31842-31853.
• 24 Bode W, Turk D, Karshikov A. The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci 1992; 01: 426-471.
• 25 Fuentes-Prior P, Iwanaga Y, Huber R. et al. Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex. Nature 2000; 404: 518-525.
• 26 Bird AP. DNA methylation and the frequency of CpG in animal DNA. Nucleic Acids Res 1980; 08: 1499-1504.
• 27 Cooper DN, Youssoufian H. The CpG dinucleotide and human genetic disease. Hum Genet 1988; 78: 151-155.
• 28 Sivasundar S, Oommen AT, Prakash O. et al. Molecular defect of ‘Prothrombin Amrita’: substitution of arginine by glutamine (Arg553 to Gln) near the Na(+) binding loop of prothrombin. Blood Cells Mol Dis 2013; 50: 182-183.
• 29 Kishimoto M, Suzuki N, Murata M. et al. The first case of antithrombin-resistant prothrombin Belgrade mutation in Japanese. Ann Hematol 2016; 95: 541-542.